Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2026-05-11 M&A Activity
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
M&A Activity Classification · 81% confidence The document is a U.S. SEC Form 8-K “Current Report” under Item 2.01 describing the completion of a tender offer and merger (acquisition) transaction—detailing the Merger Agreement, tender offer results and closing mechanics. It is an announcement of a merger/takeover and thus fits the M&A Activity category.
2026-05-11 English
10-Q - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Regulatory Filings Classification · 86% confidence The document is a Form 8-K “Current Report” filing with the SEC, notifying investors that an earnings release is attached as an exhibit. The text does not contain the actual financial results but simply furnishes the earnings release pursuant to Item 2.02. It is therefore an SEC regulatory announcement, not the earnings release itself. Under the menu-vs-meal rule it should be classified as a general regulatory filing rather than an Earnings Release or other report type.
2026-05-07 English
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
M&A Activity Classification · 100% confidence The document is a press release announcing Aurinia Pharmaceuticals' definitive merger agreement to acquire Kezar Life Sciences. It details the terms of the acquisition, including the cash per share offer and contingent value rights, the strategic review and approval by Kezar's board, and the planned tender offer process. It also includes forward-looking statements and references to future filings such as Schedule TO and Schedule 14D-9 related to the tender offer. The content focuses on merger and acquisition activity rather than financial results, governance, or other report types. Therefore, the document fits the category of M&A Activity (TAR). The document length and detail confirm it is not a brief announcement or a regulatory filing but a substantive merger announcement.
2026-04-03 English
8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
Board/Management Information Classification · 100% confidence The document is a press release announcing changes in the company's senior management, specifically the CEO transition and appointments of other executive officers. It does not contain financial data, regulatory certifications, or detailed reports. The content fits the category of Board/Management Information (MANG) as it announces changes in the company's board and senior management positions.
2026-03-23 English
4 - AURINIA PHARMACEUTICALS INC. (0001600620) (Filer)
Director's Dealing
2026-03-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.